Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients

Background and Aims: The majority of patients treated with anti-tumor necrosis factor (TNF) therapy develop anti-drug antibodies (ADAs), which might result in loss of treatment efficacy. Strict guidelines on measuring trough levels (TLs) and ADA in clinical routine do not exist. To provide real-worl...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Ilana Reinhold, Sena Blümel, Jens Schreiner, Onur Boyman, Jan Bögeholz, Marcus Cheetham, Gerhard Rogler, Luc Biedermann, Michael Scharl
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Karger Publishers 2020-11-01
Schriftenreihe:	Inflammatory Intestinal Diseases
Schlagworte:	inflammatory bowel disease trough level measurement anti-drug antibodies crohn’s disease ulcerative colitis anti-tumor necrosis factor infliximab adalimumab
Online-Zugang:	https://www.karger.com/Article/FullText/511296
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!